Genital herpes simplex virus infection in the adolescent: Special considerations for management

Pediatric Drugs

Volumn 4, Issue 5, 2002, Pages 291-297

  Stanberry, Lawrence R ^a   Rosenthal, Susan L ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADRENALIN; ALOE VERA EXTRACT; ANALGESIC AGENT; ANESTHETIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BENZOIN; CORTICOSTEROID; CRYSTAL VIOLET; DIMETHYL SULFOXIDE; FAMCICLOVIR; GINSENG EXTRACT; HERBACEOUS AGENT; HYDROGEN PEROXIDE; ICE; IODINE; LITHIUM; LYSINE; MERBROMIN; PENCICLOVIR; PERMANGANATE POTASSIUM; PHENOL DERIVATIVE; PROBIOTIC AGENT; PYRETHROID; SILVER NITRATE; TANNIN; UNINDEXED DRUG; VALACICLOVIR; VITAMIN;

ALTERNATIVE MEDICINE; CLINICAL FEATURE; COMORBIDITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG INDICATION; FOLLOW UP; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; LABORATORY TEST; LONG TERM CARE; PAIN; PALLIATIVE THERAPY; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; SCREENING TEST; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS TRANSMISSION;

EID: 0036116411     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204050-00002     Document Type: Review

References (59)

1. Herpes simplex viruses 1 and 2
2. The epidemiology of herpes simplex virus infections in adolescents
3. The pathogenesis of herpes simplex virus infections
4. A prospective study of new infections with herpes simplex virus type 1 and type 2
5. Recurrence rates in genital herpes after symptomatic first-episode infection
6. New developments in the epidemiology, natural history and management of genital herpes
7. Herpes simplex virus type 2 in the United States, 1976 to 1994
8. HSV-2 specific seroprevalence among various populations in Rome, Italy
9. The burden of infection with HSV-1 and HSV-2 in England and Wales: Implications for the changing epidemiology of genital herpes
10. Seroprevalence of herpes simplex virus type 1 and type 2 in selected German populations: Relevance for the incidence of genital herpes
11. Risk factors for the sexual transmission of genital herpes
12. Seroprevalence of and risk factors for antibodies to herpes simplex viruses, hepatitis B, and hepatitis C among southwestern hispanic and non-hispanic white women
13. Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents
14. High prevalence and incidence of sexually transmitted diseases in urban adolescent females despite moderate risk behaviors
15. Epidemiology of herpes simplex virus type 2 infections in a high-risk adolescent population
16. Demographic rather than behavioral risk factors predict herpes simplex virus type 2 infection in sexually active adolescents
17. Incidence and prevalence of chlamydia, herpes, and viral hepatitis in a homeless adolescent population
18. Seroprevalence of herpes simplex virus type 2 in African-American college women
19. Herpes simplex virus type 2 antibody in patients attending antenatal or STD clinics
20. Antenatal seroprevalence of herpes simplex virus type 2 (HSV-2) in Canadian women: HSV-2 prevalence increases throughout the reproductive years
21. Seroepidemiologic study of herpes simplex virus type 2 and cytomegalovirus among young adults in northern Jordan
22. Seroprevalence of herpes simplex virus type 2 antibodies in New Zealand sexual health clinic patients
23. Prevalence of antibodies against varicella zoster, herpes simplex (types 1 and 2), hepatitis B and hepatitis A viruses among Spanish adolescents
24. Decline of herpes simplex virus type 2 and chlamydia trachomatis infections from 1970 to 1993 indicated by a similar change in antibody pattern
25. Herpes simplex type 1 and genital herpes in Northern Ireland
26. A randomized, double-blind, comparative trial comparing high and standard dose oral acyclovir for first-episode genital herpes infections
27. First episodes of genital herpes in a Swedish STD population: A study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology
28. Changing trends in genital herpes simplex virus infection in Bergen, Norway
29. Herpes simplex virus latency and nucleoside analogues
30. Aciclovir: An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy
31. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir
32. Valaciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpes virus infections
33. Pharmacokinetics of famciclovir in man
34. CDC 1998 guidelines for treatment of sexually transmitted diseases
35. Intravenous acyclovir therapy of first episodes of genital herpes: A multicenter double-blind, placebo-controlled trial
36. Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: Results of topical, intravenous and oral therapy
37. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: A randomized, double-blind multicenter trial
38. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection: Results of an international, multicenter, double-blind randomized clinical trial
39. Recurrence rates in genital herpes after symptomatic first-episode infection
40. Risk of recurrence after first episodes of genital herpes: Relation to HSV type and antibody response
41. Valaciclovir versus acyclovir in patient-initiated treatment of recurrent genital herpes: A randomized, double-blind clinical trial
42. Treatment of recurrent genital herpes simplex infections with oral acyclovir: A controlled trial
43. A large-scale, placebo-controlled, dose-ranging trial of peroral valacyclovir for episodic treatment of recurrent herpes genitalis
44. A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes
45. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: A multicenter, double-blind, placebo-controlled trial
46. Valaciclovir for the suppression of recurrent genital HSV infection: A placebo controlled study of once-daily therapy
47. Oral famciclovir for the suppression of recurrent genital herpes: A randomized controlled trial
48. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study
49. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes
50. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection
51. Famciclovir for suppression of asymptomatic and symptomatic recurrent genital herpes shedding: A randomized, double-blind, double dummy, parallel group, placebo-controlled trial
52. BID famciclovir suppression of asymptomatic genital herpes simplex virus shedding in men
53. Suppression of subclinical shedding of herpes simplex virus type 2 in the genital tract with valacyclovir
54. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir
55. Dosage and safety of long term suppressive acyclovir therapy for recurrent genital herpes
56. Long-term suppression of recurrent genital herpes with acyclovir: A 5-year benchmark
57. Recurrence and resistance patterns of herpes simplex virus following cessation of ≥6 years of chronic suppression with acyclovir
58. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women